Evaluation of Safety and Efficacy of Periprocedural Use of Rivaroxaban and Edoxaban in Catheter Ablation for Atrial Fibrillation

Trial Profile

Evaluation of Safety and Efficacy of Periprocedural Use of Rivaroxaban and Edoxaban in Catheter Ablation for Atrial Fibrillation

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 Dec 2015

At a glance

  • Drugs Edoxaban (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Atrial fibrillation; Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top